Clinical Trial for Regenerative Medicine: Cognitive Decline, Immune Function, Overall Health, and Long-COVID Symptoms

STUDY PARTICIPATION REQUEST FORM

Eligible Participants:

  • Adults 18+: Seeking individuals to participate in groundbreaking research.

  • Symptom Experience: Those with age-related cognitive decline, immunodeficiency, functional disorders, or Long-COVID-19 symptoms.

  • OR: Healthy adults willing to donate stem cells through mini-liposuction.

Purpose of Study:

  • Investigating the potential of combined allogeneic Adipose-derived Mesenchymal Stem Cell and Hyperbaric Oxygen Treatment (HBOT) therapy.

  • Aim: To improve brain health, immune function, functional abilities, overall health, and alleviate Long-COVID-19 symptoms.

What is Required:

  • Initial Screening: 2 study visits, 4-6 hours each.

  • 9-Month Participation: Involvement in treatment and assessments.

  • Stem Cell Infusion: IV infusions (1-2 hours) at 0, 3, 6 months.

  • HBOT Sessions: 10 days, 90 minutes each, at 0, 3, 6 months.

  • Blood Tests: 9 study visits (1-2 hours each).

  • Follow-up Assessments: 5 study visits (4-6 hours each).

  • Stem Cell Donors: 1 screening visit (1 day), 1 mini-liposuction (1 day), 2 days recovery.

Benefits:

  • Compensation: 

  • $50 for each 1–2-hour study visit (9 total).

  • $100 for each 4–6-hour study visit (7 total).

  • Stem cell donors $250 per day for 4 days.

  • Comprehensive Health Assessments: Free physical exam, cardiovascular, metabolic, immune, aging, and medical safety blood tests, ECG, fitness, strength, DEXA, resting energy expenditure, physical function, lung function, brain function, skin health and retina scans.

  • Free Intervention: Those in the treatment group will receive the study intervention free of charge.

  • Important Note: We cannot guarantee personal benefits from study participation.

Full Study Title:

  • Safety and Tolerability of Allogeneic Adipose-Derived Mesenchymal Stem Cells Administered Intravenously in Combination with Hyperbaric Oxygen [100% inspired O2 medical grade oxygen gas at 2.4 Atmospheres Absolute (ATA)] Therapy [HoskAge (HHWC01-AD-MSCs/HBOT)] in Adults with Age-related Cognitive Decline, Immunodeficiency and Functional disorders.

This research study is conducted under ethical guidelines and oversight.